Sanofi
€76.15+€0.64 (+0.85%)
Sanofi’s quoted price sits in the lower half of its reported 52-week range, 16.13% below the high.
PAR · EMEIS.PA · EUR
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 04:35 PM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
Emeis’s quoted price sits in the lower half of its reported 52-week range, 34.81% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Emeis’s forward annual dividend is €76.64 per share, paid annual. The forward yield is 734.77% at the quoted price. Future payments can change.
Dividend payment history is currently unavailable.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
BEHIND THE RESULTS
Emeis’s next earnings report is currently expected on May 7, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Emeis’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Emeis Société anonyme operates as a prominent provider of diverse healthcare services, encompassing the management of nursing homes, assisted-living facilities, specialized post-acute and rehabilitation hospitals, and psychiatric treatment centers. Within its elderly care residences, the company delivers tailored support alongside comprehensive logistical and residential amenities, including comfortable accommodation, meal services, laundry, and room maintenance. These facilities also enrich residents' lives with a variety of daily events, recreational activities, and therapeutic workshops. Emeis's post-acute and rehabilitation hospitals are equipped to treat a wide array of medical conditions, such as geriatric issues, musculoskeletal and neurological disorders, cardiovascular and hematological ailments, oncology recovery, and care for individuals in persistent vegetative or minimally conscious states. The psychiatric hospitals address an extensive spectrum of mental health concerns, ranging from mood, anxiety, and obsessive-compulsive disorders to addictions, eating disorders, sleep disturbances, personality disorders, age-related psychiatric conditions, psychosis, and stress-induced conditions like burnout, chronic fatigue syndrome, fibromyalgia, psychosomatic issues, and post-traumatic stress disorder. Furthermore, they offer specialized psychiatric care for geriatrics, children, young adults, and parent-child dynamics, serving both public and private patients. Complementing its institutional offerings, Emeis also provides comprehensive home care solutions. These include practical domestic assistance such as cleaning, meal preparation, ironing, gardening, and running errands; daily living support encompassing day or night supervision and aid with hygiene and meals; and mobility assistance. Founded in 1989 and headquartered in Puteaux, France, the company maintains an expansive international presence, with operations spanning numerous countries across Europe, Latin America, and Asia, including France, Belgium, Spain, Italy, Ireland, Switzerland, Austria, Germany, the Czech Republic, Poland, the Netherlands, Luxembourg, Portugal, Brazil, Russia, Slovenia, Uruguay, Colombia, Mexico, Chile, Latvia, Croatia, and China.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:43 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€76.15+€0.64 (+0.85%)
Sanofi’s quoted price sits in the lower half of its reported 52-week range, 16.13% below the high.
€178.20+€0.50 (+0.28%)
EssilorLuxottica S.A.’s quoted price sits in the lower half of its reported 52-week range, 44.97% below the high.
€228.40+€7.00 (+3.16%)
Sartorius Stedim Biotech S.A.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
€155.80+€2.90 (+1.9%)
Ipsen S.A.’s quoted price sits in the upper half of its reported 52-week range, 10.46% below the high.
€90.15-€0.85 (-0.93%)
bioMérieux S.A.’s quoted price sits in the lower half of its reported 52-week range, 22.35% below the high.
€3.36+€0.11 (+3.38%)
Clariane SE’s quoted price sits in the lower half of its reported 52-week range, 24.05% below the high.
€8.84-€0.10 (-1.12%)
Ramsay Générale de Santé S.A.’s quoted price sits in the lower half of its reported 52-week range, 23.46% below the high.
€24.10+€0.20 (+0.84%)
LNA Santé S.A.’s quoted price sits in the lower half of its reported 52-week range, 33.97% below the high.